VIDO-InterVac offers a range of services from discovery to clinical trials. This includes:
Pathogenesis and animal model development:
We have substantial experience studying pathogenesis of risk group 2 and 3 infectious diseases including microbe biology and transmission, examining immune and host-pathogen responses (e.g. flow cytometry, confocal microscopy, small live animal in vivo imaging), and developing animal models of disease.
VIDO-InterVac offers industry partners the opportunity to advance their research using animal models. Our Clinical Research & Animal Care team has an extensive list of established animal models and has the capability to develop challenge models to meet research needs.
Formulation and development support:
VIDO-InterVac has the expertise and infrastructure to assist partners in the development and evaluation of vaccine candidates and anti-infective compounds for risk group 2 and 3 infectious diseases. Our researchers can assist with antigen identification, vaccine formulation, and development of novel delivery methods (e.g. mucosal, live viral vectors, and needle-free).
Vaccine safety and efficacy testing:
Evaluating the safety and efficacy of vaccine candidates is the core of VIDO-InterVac’s contract research services offering. Our facility was designed to allow for a range of experimental designs from preclinical testing (human) and licensing trials (animals). Additionally, we are one of the only infectious disease and vaccine research facilities in North America with containment level 3 large animal capacity.